Cargando…

Cardiovascular Benefits of GLP-1 Receptor Agonism: Is Inflammation a Key?

[Figure: see text]

Detalles Bibliográficos
Autores principales:	Marx, Nikolaus, Libby, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314960/ https://www.ncbi.nlm.nih.gov/pubmed/30623144 http://dx.doi.org/10.1016/j.jacbts.2018.11.008

Ejemplares similares

The therapeutic potential of GLP‐1 receptor biased agonism
por: Jones, Ben
Publicado: (2021)

GLP-1/glucagon receptor co-agonism for treatment of obesity
por: Sánchez-Garrido, Miguel A., et al.
Publicado: (2017)

Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice
por: Clemmensen, Christoffer, et al.
Publicado: (2015)

The Extracellular Surface of the GLP-1 Receptor Is a Molecular Trigger for Biased Agonism
por: Wootten, Denise, et al.
Publicado: (2016)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Structural analysis of the dual agonism at GLP-1R and GCGR
por: Li, Yang, et al.
Publicado: (2023)

A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
por: Hornigold, David C., et al.
Publicado: (2018)

Pokémon Go: cardiovascular benefit or injury risk?
por: Sharma, Pranev, et al.
Publicado: (2016)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
por: Borner, Tito, et al.
Publicado: (2021)

GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance
por: Taher, Jennifer, et al.
Publicado: (2014)

Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
por: Costa, Alessia, et al.
Publicado: (2021)

Combined GIP receptor and GLP1 receptor agonism attenuates NAFLD in male APOE∗3-Leiden.CETP mice
por: Ying, Zhixiong, et al.
Publicado: (2023)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

Lipoprotein (a): A Frustrating Final Frontier in Lipid Management?
por: Libby, Peter
Publicado: (2016)

“Let's Stay Together”; GIP and GLP-1 dual agonism in the treatment of metabolic disease
por: DiMarchi, Richard D.
Publicado: (2018)

Cardiovascular Benefits of Native GLP-1 and its Metabolites: An Indicator for GLP-1-Therapy Strategies
por: Li, Junfeng, et al.
Publicado: (2017)

Molecular mechanism of agonism and inverse agonism in ghrelin receptor
por: Qin, Jiao, et al.
Publicado: (2022)

GLP-1R Agonism Enhances Adjustable Gastric Banding in Diet-Induced Obese Rats
por: Habegger, Kirk M., et al.
Publicado: (2013)

CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
por: Modvig, Ida M., et al.
Publicado: (2020)

Taking Sex Seriously: An Oft-Overlooked Biological Variable
por: Libby, Peter, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Internal Bleeding: Is Intraplaque Hemorrhage a Decoration or a Driver?
por: Michel, Jean-Baptiste, et al.
Publicado: (2018)

Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
por: Jun, Seungho, et al.
Publicado: (2019)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

Connecting inflammation with glutamate agonism in suicidality
por: Erhardt, Sophie, et al.
Publicado: (2013)

Time-dependent effect of GLP-1 receptor agonists on cardiovascular benefits: a real-world study
por: Piccini, Sara, et al.
Publicado: (2023)

Costs and benefits of treatment of myocardial infarction
por: Simoons, M. L.
Publicado: (2013)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Partial agonism improves the anti-hyperglycaemic efficacy of an oxyntomodulin-derived GLP-1R/GCGR co-agonist
por: Pickford, Phil, et al.
Publicado: (2021)

Agonism and Antagonism at the Insulin Receptor
por: Knudsen, Louise, et al.
Publicado: (2012)

Klotho: a link between cardiovascular and non-cardiovascular mortality
por: Lanzani, Chiara, et al.
Publicado: (2020)

Cardiovascular changes in young renal failure patients
por: Tøndel, Camilla, et al.
Publicado: (2021)

Health literacy skills and the benefits of cardiovascular disease prevention
por: Peters, R. J. G.
Publicado: (2017)

Comment to the Article “Prevention of B Thalassemia in Northern Israel - A Cost-Benefit Analysis” by Koren et al.1
por: Amato, Antonio
Publicado: (2014)

Do elderly patients benefit from implantable-cardioverter defibrillators?
por: de Groot, J. R.
Publicado: (2014)

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
por: Tanday, Neil, et al.
Publicado: (2021)

Early detection of iron overload in the heart: a key role for MRI!
por: Baur, Leo H. B.
Publicado: (2009)

Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes
por: Ridge, T, et al.
Publicado: (2012)

Evaluation of efficacy- versus affinity-driven agonism with biased GLP-1R ligands P5 and exendin-F1
por: Marzook, Amaara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_n48vl1662cvklifbl8g0u09soe